Mammary Cell News Volume 10.07 | Feb 22 2018

TOP STORY

Photo-Immobilized EGF Chemical Gradients Differentially Impact Breast Cancer Cell Invasion and Drug Response in Defined 3D Hydrogels

Scientists demonstrated that epidermal growth factor (EGF) gradients can differentially influence breast cancer cell invasion and drug response in cell lines with different EGF receptor expression levels. [Biomaterials] Abstract

(Ranked by impact factor of the journal)

Interaction between STAT3 and GLI1/tGLI1 Oncogenic Transcription Factors Promotes the Aggressiveness of Triple-Negative Breast Cancers and HER2-Enriched Breast Cancer

Researchers observed that co-overexpression of signal transducer and activator of transcription 3 (STAT3) with glioma oncogene homolog 1 (GLI1)/truncated GLI1 (tGLI1) promoted the ability of breast cancer cells to form mammospheres and that STAT3 only cooperates with tGLI1 in immortalized mammary epithelial cells. [Oncogene] Abstract

Investigation of Adhesive Interactions in the Specific Targeting of Triptorelin-Conjugated PEG-Coated Magnetite Nanoparticles to Breast Cancer Cells

The authors report a combination of experimental and computational approaches to evaluate the adhesion between triptorelin-conjugated poly-(ethylene glycol) (PEG)-coated magnetite nanoparticles and breast cells. [Acta Biomater] Abstract

Plasticity and Intratumoral Heterogeneity of Cell Surface Antigen Expression in Breast Cancer

Researchers found that surface CD9, CD29, CD49c, and integrin β5 are lost in breast cancer cells that underwent epithelial-to-mesenchymal transition in vivo. [Br J Cancer] Abstract

BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells

Investigators employed derivatives of BT-549 and MDA-MB-468 triple-negative breast cancer cell lines that were adapted to grow in the presence of either 5-fluorouracil, doxorubicin or docetaxel in an aim to identify molecular pathways involved in the adaptation to drug-induced cell killing. [Neoplasia] Full Article

SMURF1 Facilitates Estrogen Receptor α Signaling in Breast Cancer Cells

Scientists identified that the E3 ligase SMURF1 facilitates ER alpha signaling. They showed that depletion SMURF1 of decreases ER alpha positive cell proliferation in vitro and in vivo. [J Exp Clin Cancer Res] Full Article

Histone Modification Profiling in Breast Cancer Cell Lines Highlights Commonalities and Differences among Subtypes

To define alterations in epigenetic landscapes in breast cancers, the authors profiled the distributions of 8 key histone modifications by ChIP-Seq, as well as primary and steady state transcriptomes, across 13 distinct cell lines that represent 5 molecular subtypes of breast cancer and immortalized human mammary epithelial cells. [BMC Genomics] Full Article

Arctigenin Inhibits the Activation of the mTOR Pathway, Resulting in Autophagic Cell Death and Decreased ER Expression in ER-Positive Human Breast Cancer Cells

Researchers examined the effect of arctigenin on estrogen receptor (ER)α-positive MCF-7 human breast cancer cells to determine whether the consumption of arctigenin is safe for patients with breast cancer. [Int J Oncol] Abstract

Synergistic Promoting Effects of Pentoxifylline and Simvastatin on the Apoptosis of Triple-Negative MDA-MB-231 Breast Cancer Cells

Pentoxifylline, a xanthine family molecule and simvastatin, an anti-hypercholesterolemic agent, have recently been considered as sensitizers to chemotherapy and radiotherapy. Scientists evaluated their antitumor synergistic effects on MDA-MB-231 breast cancer cells characterized by the triple-negative phenotype. [Int J Oncol] Abstract

Receptor Tyrosine Kinases (RTKs) in Breast Cancer: Signaling, Therapeutic Implications and Challenges

RTKs are known to regulate various downstream signaling pathways such as MAPK, PI3K/Akt and JAK/STAT. These pathways have a pivotal role in the regulation of cancer stemness, angiogenesis and metastasis. [Mol Cancer] Full Article

Checkpoint Inhibitors in Triple-Negative Breast Cancer (TNBC): Where to Go from Here

The authors review the current literature on checkpoint inhibitors in TNBC with a focus on PD-1/PD-L1 antibodies and discuss combination strategies and novel approaches for improving antitumor immunity and clinical outcome. [Cancer] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

‘Local Environment’ Plays Key Role in Breast Cancer Progression

Deep Parikh, a doctoral candidate at Stevens Institute of Technology, presented his work exploring the role physical changes within a cancer cells’ local environment play in the aggressiveness of breast cancer. [Press release from Biophysical Society (Newswise Inc.) discussing research presented at the 62^nd Biophysical Society Annual Meeting, San Francisco] Press Release | Abstract

BerGenBio Completes Recruitment into First Stage of Phase II Breast Cancer Trial with Selective AXL Inhibitor Bemcentinib Combined with KEYTRUDA^®

BerGenBio ASA announced that it has completed enrollment, ahead of schedule, of the planned 28 patients into the first stage of its Phase II clinical trial evaluating its investigational oral selective AXL inhibitor bemcentinib in combination with anti-PD-1 therapy KEYTRUDA^® as a potential new treatment regimen for advanced breast cancer. [BerGenBio ASA (PR Newswire Association LLC.)] Press Release

MD Anderson Receives $22 Million in CPRIT Funding for Research, Prevention and Recruitment

The University of Texas MD Anderson Cancer Center was awarded $22.3 million from the Cancer Prevention and Research Institute of Texas (CPRIT), accounting for 30 percent of the $73.5 million in awards CPRIT. The awards included $16.3 million for individual investigator research including awards for cancer in children and adolescents, computational biology, clinical translation, and prevention and early detection. [MD Anderson Cancer Center] Press Release

Half of Canada’s Government Scientists Still Feel Muzzled

More than half of government scientists in Canada—53%—do not feel they can speak freely to the media about their work, even after Prime Minister Justin Trudeau’s government eased restrictions on what they can say publicly, according to a survey released by a union that represents more than 16,000 federal scientists. [ScienceInsider] Editorial

U.K. Scientists Increasingly Anxious about Brexit Confusion

With the second phase of Brexit negotiations approaching, scientists in the United Kingdom are urging their government to clarify its position on funding agreements and migration of research talent after the country separates from the European Union in March 2019. [ScienceInsider] Editorial

Meet the Scientists Running to Transform Congress in 2018

The first big test for the cohort of science candidates comes on 6 March, when Texas holds the nation’s first primary elections. Several candidates are running to become Democratic nominees in that Lone Star state’s House districts. [ScienceInsider] Editorial

NEW Gordon Research Conferences: Notch Signaling in Development, Regeneration and Disease
July 22-27, 2018
Lewiston, Maine, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Researcher – Genomic Breast Cancer Epidemiology (Karolinska Institutet)

Computational Biologist – Cancer Research (Cancer Research UK Manchester Institute)

Postdoctoral Researcher – Breast Cancer (University of Oxford)

Postdoctoral Scientist Opportunities – Biomedical Research (Cedars-Sinai)

Postdoctoral Fellow – Cancer Research (Memorial Sloan Kettering Cancer Center)

Postdoctoral Position – Clinical Bioinformatics Improving Breast Cancer Therapies (German Cancer Research Center)

Research Fellow – Breast Immunology (Dana-Farber Cancer Institute)

Postdoctoral Fellowship – Cancer Molecular Genetics and Therapeutics (Massachusetts General Cancer Center)

Postdoctoral Fellow – Cancer Biology (University of Arkansas for Medical Science)

Postdoctoral Research Associate – Cancer Biology (King’s College London)

Postdoctoral Researcher – Development of Novel Cancer Therapies (University of Oxford)

Cancer Bioinformatician – Breast Cancer Research (The Institute of Cancer Research)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.